Navigation Links
Nicotine May Help Prevent Damage from Bioterrosim Toxin and Growth Factors in Heart Disease News from Molecular Medicine
Date:5/6/2009

Nicotine has potent anti-inflammatory properties and British scientists have now found that it is helpful in delaying the effects of ricin, the toxic substance feared in biologic warfare.

Manhasset, NY (Vocus) May 6, 2009 -- Nicotine has potent anti-inflammatory properties and British scientists have now found that it is helpful in delaying the effects of ricin, the toxic substance feared in biologic warfare. Jon G. Mabley and his colleagues at the University of Brighton found that nicotine works through the cholinergic inflammatory pathway to block the anti-inflammatory and tissue-destroying effects of ricin, a compound derived from castor beans. The study was conducted in laboratory models but the scientists believe that nicotine agonists could potentially be used in patients exposed to ricin as a stopgap measure before other treatments can take effect.

The British investigators studied the effect of nicotine on animals exposed to ricin and found it reduced death and organ failure. "The protective effect of nicotine appears to be associated with its anti-inflammatory effect, suggesting a possible therapeutic strategy of activating the cholinergic anti-inflammatory pathway following ricin exposure to protect against multiple organ failure. The overall effect of nicotine on maintaining liver and kidney function while reducing systemic inflammation may account for the reduced mortality observed with ricin exposure," the authors wrote.

Activation of the anti-inflammatory cholinergic pathway is now undergoing testing to reduce inflammation in a wide range of diseases.

In another study that appears in the May-June 2009 issue of Molecular Medicine, a team of scientists from Argentina report identifying genomic instability in the mitochondria of cells culled from breast cancer tissue. The scientists analyzed two markers along the mitochondrial DNA and found 38 of the 94 tissue samples showed some genetic instability, suggesting that this could be the mechanism that allows cancer cells to take hold.

You can view all of the articles in the May-June issue by visiting the journal's Web site at www.molmed.org.

Molecular Medicine is a bimonthly journal published by The Feinstein Institute for Molecular Research. The peer-reviewed journal strives to understand normal body functioning and disease pathogenesis at the molecular level, which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. The journal, a bimonthly publication, serves as a forum through which scientists and researchers can communicate recent discoveries to a multi-disciplinary, international audience interested in understanding and curing disease.

To listen to the latest podcast on these studies visit www.molmed.org/podcast.html (episode 46).

###

Read the full story at http://www.prweb.com/releases/2009/05/prweb2395344.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Nicotine Replacement May Help Smokers Quit Gradually
2. Pennsylvania to Offer Free Nicotine Replacement Therapy Kits Beginning Feb. 2
3. Nicotine gum effective for gradual smoking reduction and cessation
4. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
5. FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Give FDA Authority Over Tobacco Products
6. Todays Smokers More Addicted to Nicotine
7. US Nicotine Addiction Reaches 15-Year High
8. American Legacy Foundation(R) Statement of Support for the Federal Trade Commission Reversal on Tar and Nicotine Yield Statements on Cigarettes
9. FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Go Further by Giving FDA Authority Over Tobacco Products
10. Potential dangers faced by narcoleptics who use nicotine outlined in new abstract
11. Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nicotine May Help Prevent Damage from Bioterrosim Toxin and Growth Factors in Heart Disease News from Molecular Medicine
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Event in New York City, with long-time partners The Paul Foundation, on November ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 /PRNewswire/ ... SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the ... by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) ... Novartis today announced that the data are being featured ... American Society of Hematology (ASH) Annual Meeting and ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: